Top Page
Scienture Holdings
(NASDAQ:SCNX)
Scienture Holdings (SCNX) vs. SPDR S&P 500 ETF (SPY)
Scienture Holdings Business Overview & Revenue Model
Scienture Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 653.39K | 136.64K | 1.36M | 10.25M | 9.89M | 17.12M |
| Gross Profit | 562.66K | 6.00K | 49.03K | 5.52M | 4.75M | 5.71M |
| EBITDA | -16.54M | -17.39M | -6.29M | -1.87M | -5.15M | -2.40M |
| Net Income | -20.55M | 9.07M | -17.84M | -3.47M | -5.32M | -2.54M |
Balance Sheet | ||||||
| Total Assets | 104.83M | 104.85M | 12.53M | 3.71M | 5.77M | 9.79M |
| Cash, Cash Equivalents and Short-Term Investments | 355.69K | 308.10K | 314.00 | 1.09M | 3.12M | 5.92M |
| Total Debt | 2.02M | 3.53M | 6.76M | 1.58M | 1.25M | 627.46K |
| Total Liabilities | 22.16M | 25.78M | 11.99M | 3.37M | 2.00M | 1.11M |
| Stockholders Equity | 82.67M | 79.07M | 542.35K | 763.14K | 3.77M | 8.68M |
Cash Flow | ||||||
| Free Cash Flow | -11.11M | -14.28M | -2.23M | -1.56M | -2.59M | -2.25M |
| Operating Cash Flow | -11.11M | -14.27M | -2.23M | -1.56M | -2.57M | -2.21M |
| Investing Cash Flow | 0.00 | 27.55M | -275.72K | -427.85K | -22.60K | -37.51K |
| Financing Cash Flow | 11.04M | -12.98M | 1.41M | -35.17K | -208.18K | 5.30M |
Scienture Holdings Technical Analysis
Scienture Holdings Risk Analysis
Scienture Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ― | ― | ― | ― | -14.88% | 54.76% | |
43 Neutral | $16.32M | ― | -8.96% | ― | -24.64% | 92.19% | |
41 Neutral | $28.21M | -0.28 | -44.11% | ― | -73.18% | 92.38% | |
39 Underperform | $17.36M | -0.24 | ― | ― | 187.24% | 82.90% | |
27 Underperform | $15.45M | -0.02 | -182.56% | ― | -21.88% | 68.40% |
Scienture Holdings Corporate Events
On November 17, 2025, Scienture Holdings, Inc. released a revised investor presentation on its website, aimed at engaging analysts, potential investors, and other stakeholders. The presentation, which is part of the company’s ongoing communication strategy, includes forward-looking statements about its projects, potential financial performance, and growth opportunities, highlighting the inherent risks and uncertainties that could impact future results.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
On November 12, 2025, Scienture Holdings, Inc. held its 2025 Annual Meeting of Stockholders virtually, where stockholders voted on six key proposals. The stockholders elected five directors to the board and approved amendments to the 2019 Equity Incentive Plan and a potential future offering of common stock. However, they rejected the proposal to increase the number of authorized shares of common and preferred stock. Additionally, the stockholders approved granting the board discretion to implement a reverse stock split and the option to adjourn the meeting if necessary, although the latter was deemed unnecessary due to sufficient votes.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
On November 7, 2025, Scienture Holdings, Inc. filed a prospectus supplement with the SEC to increase the amount of common stock it can sell under an equity distribution agreement with Maxim Group LLC to $150 million. This move allows the company to potentially raise significant capital, impacting its financial strategy and market operations.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
On October 24, 2025, Scienture Holdings, Inc. filed a prospectus supplement with the SEC to increase the amount of its common stock eligible for sale under a previous agreement with Maxim Group LLC, aiming for an aggregate offering price of up to $9,592,009. The company has already sold approximately $13,252,250 in securities over the past 12 months, leaving $9,592,009 available for future sale, which could impact its financial strategy and market presence.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
On October 14, 2025, Scienture Holdings, Inc. received a notice from Nasdaq indicating non-compliance with the Minimum Bid Price Requirement, as its stock price remained below $1.00 for 30 consecutive business days. The company has until April 13, 2026, to regain compliance by ensuring its stock price meets or exceeds $1.00 for ten consecutive business days. This notice does not immediately affect the stock’s listing or trading, and the company is optimistic about regaining compliance, though there is no guarantee.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
Scienture Holdings, Inc., through its subsidiary Scienture, LLC, entered into a Second Amendment of a Loan and Security Agreement with NVK Finance LLC on October 10, 2025, extending the loan maturity date to December 8, 2025, and agreeing to pay various fees and issue shares to NVK. By October 15, 2025, Scienture had fully repaid the NVK Loan. Additionally, on October 14, 2025, Scienture entered into a note purchase agreement with Streeterville Capital, LLC, issuing a senior secured promissory note for $3,911,111.11. The net proceeds of $3,500,000 were used to repay the NVK Loan and for other corporate purposes, with the note due in seven months and carrying a 9% interest rate.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
On October 1, 2025, Scienture Holdings, Inc. amended its bylaws to change the quorum requirement for stockholder meetings from a majority to one-third of voting stock. This adjustment is poised to streamline decision-making processes and potentially increase shareholder participation by lowering the threshold needed to conduct business.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
On October 3, 2025, Scienture Holdings, Inc. amended the terms of its convertible debentures with Arena Finance Markets, LP and Arena Special Opportunities III LP, revising the conversion price to $2.4861 per share. This agreement facilitates the full conversion of the debentures into common stock, leading to the termination of all obligations, security interests, and transaction documents between the parties, effectively releasing Scienture Holdings from its financial commitments to the Arena Investors.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.
On September 19, 2025, Scienture Holdings, Inc. entered into an Equity Distribution Agreement with Maxim Group LLC to act as the sole sales agent for the offer and sale of up to $9,200,000 worth of its common stock. This agreement allows for “at the market” offerings on The Nasdaq Capital Market, with the company retaining the flexibility to determine the timing and amount of shares sold. The agreement includes a 3% commission for Maxim Group and provisions for termination or suspension of the offering. This strategic move could potentially impact Scienture Holdings’ market positioning by providing financial flexibility, although there is no guarantee of sales or the timing thereof.
The most recent analyst rating on (SCNX) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Scienture Holdings stock, see the SCNX Stock Forecast page.